PT - JOURNAL ARTICLE AU - Trang, Khanh B. AU - Sharma, Prabhat AU - Cook, Laura AU - Mount, Zachary AU - Thomas, Rajan M. AU - Kulkarni, Nikhil N. AU - Pahl, Matthew C. AU - Pippin, James A. AU - Su, Chun AU - Kaestner, Klaus H. AU - O’Brien, Joan M. AU - Wagley, Yadav AU - Hankenson, Kurt D. AU - Jermusyk, Ashley AU - Hoskins, Jason W. AU - Amundadottir, Laufey T. AU - Xu, Mai AU - Brown, Kevin M. AU - Anderson, Stewart A. AU - Yang, Wenli AU - Titchenell, Paul M. AU - Seale, Patrick AU - Zemel, Babette S. AU - Chesi, Alessandra AU - Romberg, Neil AU - Levings, Megan K. AU - Grant, Struan F.A. AU - Wells, Andrew D. TI - 3D chromatin-based variant-to-gene maps across 57 human cell types reveal the cellular and genetic architecture of autoimmune disease susceptibility AID - 10.1101/2024.08.12.24311676 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.12.24311676 4099 - http://medrxiv.org/content/early/2024/08/12/2024.08.12.24311676.short 4100 - http://medrxiv.org/content/early/2024/08/12/2024.08.12.24311676.full AB - A portion of the genetic basis for many common autoimmune disorders has been uncovered by genome-wide association studies (GWAS), but GWAS do not reveal causal variants, effector genes, or the cell types impacted by disease-associated variation. We have generated 3D genomic datasets consisting of promoter-focused Capture-C, Hi-C, ATAC-seq, and RNA-seq and integrated these data with GWAS of 16 autoimmune traits to physically map disease-associated variants to the effector genes they likely regulate in 57 human cell types. These 3D maps of gene cis-regulatory architecture are highly powered to identify the cell types most likely impacted by disease-associated genetic variation compared to 1D genomic features, and tend to implicate different effector genes than eQTL approaches in the same cell types. Most of the variants implicated by these cis-regulatory architectures are highly trait-specific, but nearly half of the target genes connected to these variants are shared across multiple autoimmune disorders in multiple cell types, suggesting a high level of genetic diversity and complexity among autoimmune diseases that nonetheless converge at the level of target gene and cell type. Substantial effector gene sharing led to the common enrichment of similar biological networks across disease and cell types. However, trait-specific pathways representing potential areas for disease-specific intervention were identified. To test this, we pharmacologically validated squalene synthase, a cholesterol biosynthetic enzyme encoded by the FDFT1 gene implicated by our approach in MS and SLE, as a novel immunomodulatory drug target controlling inflammatory cytokine production by human T cells. These data represent a comprehensive resource for basic discovery of gene cis-regulatory mechanisms, and the analyses reported reveal mechanisms by which autoimmune-associated variants act to regulate gene expression, function, and pathology across multiple, distinct tissues and cell types.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Institutes of Health, National Institute of Allergy and Infectious Diseases AI146026 (N.R., A.D.W., S.F.A.G.) Canadian Institutes of Health Research FDN-154304, award from the BC Children's Hospital Research Institute and Canada Research Chair in Engineered Immune Tolerance (M.K.L.) BC Children's Hospital Foundation Bertram Hoffmeister Postdoctoral Fellowship (L.C.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Given the use of de-identified datasets and biospecimens was not considered human subjects research, ethical oversight was waived by the Institutional Review Board of the Children's Hospital of Philadelphia.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data and supplementary tables from this study are available upon reasonable request to the authors and will be published following peer-reviewed acceptance.